Study to Evaluate H56:IC31 in Preventing Rate of TB Recurrence

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE2

Total Enrollment

831 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-01-31

Study Completion Date

2024-03-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a phase 2, double-blind, randomized (1:1), placebo-controlled trial with two parallel groups.

* H56:IC31 (investigational vaccine)
* Placebo

900 HIV-negative adults with a diagnosis of drug susceptible pulmonary TB are planned to be included, recruited from TB clinics with established relationships to the trial sites at the start of their TB treatment.

5 study sites in South Africa: 2 sites from the AURUM institute (Klerksdorp and Tembisa) and 3 in Cape Town at TASK Applied Science (TASK), the University of Cape Town Lung Institute (UCTLI) and South African Tuberculosis Vaccine Initiative (SATVI) under UCT, respectively.

1 study site in Tanzania (TZ): 1 site at Mbeya Medical Research Centre (MMRC) under the National Institute for Medical Research (NIMR).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Phase II Study of H56:IC31 in Healthy Adolescents

NCT03265977

Tuberculosis Infection

WITHDRAWN PHASE2

Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in Healthy Volunteers

NCT05537038

Tuberculosis

COMPLETED PHASE1

Tuberculosis Prevention for HIV Infected Adults

NCT00057122

HIV Infections Tuberculosis

COMPLETED PHASE3

TB Sequel: Pathogenesis and Risk Factors of Long-term Sequelae of Pulmonary TB

NCT03251196

Respiratory Tract Infections Tuberculosis, Pulmonary

UNKNOWN

Phase 2a ID93 + GLA-SE Vaccine Trial in TB Patients After Treatment Completion

NCT02465216

Pulmonary Tuberculosis

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a phase 2, double-blind, randomized (1:1), placebo-controlled trial with two parallel groups.

* H56:IC31 (investigational vaccine)
* Placebo

900 HIV-negative adults with a diagnosis of drug susceptible pulmonary TB are planned to be included, recruited from TB clinics with established relationships to the trial sites at the start of their TB treatment.

5 study sites in South Africa: 2 sites from the AURUM institute (Klerksdorp and Tembisa) and 3 in Cape Town at TASK Applied Science (TASK), the University of Cape Town Lung Institute (UCTLI)) and South African Tuberculosis Vaccine Initiative (SATVI) under UCT, respectively.

1 study site in Tanzania (TZ): 1 site at Mbeya Medical Research Centre (MMRC) under the National Institute for Medical Research (NIMR).

Preclinical data suggest H56:IC31 may be more efficacious if administered while patients are still on treatment. Following the national guidelines for TB treatment in South Africa and Tanzania, we will obtain sputum samples from patients towards the end of treatment at about the same time they are obtained within the national TB control programmes, and if the sputum is smear negative, the criterion for successful treatment within TB programmes, the individual will be eligible for randomization and vaccination towards the end of their six-month treatment period.

As this is a proof of concept TB vaccine study, HIV positive individuals have been excluded as it is not yet known what effect HIV infection may have on the immune response to the vaccine. However, HIV positive individuals are an important population to include in future studies should efficacy be demonstrated in this study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tuberculosis, Pulmonary

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

2 Cohorts - H56:IC31 and Placebo. First 150 participants will be in a safety group with additional scheduled evaluations.

Primary Study Purpose

PREVENTION

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

The unblinded persons in the study are the study vaccine manager (and designee) who manages the participant inventory log(s) at the trial site, the unblinded site staff, and the unblinded clinical trial site monitor(s) responsible for monitoring the investigational product at the trial site. All unblinded persons must take care to not reveal individual participant treatment assignments to any blinded member of the study team. There is an unblinded contact person at the sponsor's site in order to manage queries from the unblinded site staff or the unblinded monitors in the trial.

The study vaccine manager (and designee) should be a designated site team member, such as the study pharmacist. Unblinded site staff must not participate in the evaluation of adverse events.

The randomization list will be provided by the unblinded statistician and will be implemented as a module in the eCRF.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

H56:IC31

The H56 fusion protein is formulated with IC31 in a GMP-compliant environment in a ready to use final formulated vaccine.

H56:IC31 is administered twice with a 56 days (+/-10) interval, as 5 μg H56 adjuvanted with IC31 consisting of 500 nmol KLK and 20 nmol ODN1a, in a total volume of 0.5mL by the intramuscular route in the deltoid area using standard aseptic technique.

Group Type EXPERIMENTAL

H56:IC31

Intervention Type BIOLOGICAL

5ug H56/500 nmol IC31

Placebo

Sterile saline for injection

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type BIOLOGICAL

Sterile saline for injection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

H56:IC31

5ug H56/500 nmol IC31

Intervention Type BIOLOGICAL

Placebo

Sterile saline for injection

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

H56

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Completed the written informed consent process.
2. Agrees to give access to medical records for trial related purposes.
3. Was HIV-negative (self-reported) with a diagnosis of drug susceptible pulmonary TB at the start of the TB treatment.
4. Able to provide 2 separate sputum samples within ≤ 7 days of starting TB treatment. Participants are not expected to provide sputum samples prior to starting TB treatment if their 1st screening visit (V1) is performed on the same day as their 2nd screening visit (V2).
5. Confirmed Mtb negative by smear AFB microscopy of 2 separate sputum samples taken at V2. Participants unable to produce sputum, but considered asymptomatic by the investigator, may be considered Mtb negative and eligible for inclusion.
6. Confirmed HIV negative at V2.
7. Completed ≥ 5 months (22 weeks) of TB treatment with treatment still ongoing at the time of the 1st vaccination and total treatment time not extended beyond 28 weeks.
8. Aged ≥ 18 years on the date of V1 and ≤ 60 years on the date of V3= Day 0.
9. Agrees to stay in contact with the clinical trial site for the duration of the trial, provide updated contact information as necessary, and has no current plans to move from the area for the duration of the trial.

Exclusion Criteria

1. Diagnosis or co-diagnosis of extra pulmonary TB.
2. Hospitalized for the current episode of drug susceptible pulmonary TB disease.
3. History of or ongoing severe disease that in the opinion of the investigator might affect the safety of the participant or the immunogenicity of the investigational product.
4. Insulin dependent diabetes.
5. History of allergic disease or reactions likely to be exacerbated by any component of the investigational product.
6. History or laboratory evidence of immunodeficiency, autoimmune disease or immunosuppression.
7. History of chronic hepatitis.
8. Severe anemia, defined as hemoglobin less than 10 g/dL or a hematocrit less than 30% based on most recent hematology obtained before randomization.
9. History of receipt of treatment against active TB, prior to the current treatment episode, within the last 5 years
10. Receipt of any investigational TB vaccine previously.
11. Receipt or planned receipt of any investigational drug or investigational vaccine from V1 through V8= Day 421.
12. Receipt or planned receipt of any licensed vaccine from V1 through V6= Day 70, except for SARS-Cov-2 vaccines recommended by national vaccination programs which will be allowed if given \> 28 days before and from the time of administration of clinical trial product.
13. Receipt of treatment likely to modify the immune response (e.g. blood products, immunoglobulins, immunosuppressive treatment) within 42 days before V3= Day 0 through V6= Day 70. Inhaled and topical corticosteroids are permitted.
14. Has a body mass index (BMI) \< 13 (weight, kg / height, m2) on the date of V1.
15. Female participants of childbearing potential (not sterilized, menstruating or within 1 year of last menses, if post-menopausal): if not willing to use an acceptable method to avoid pregnancy (sterile sexual partner, sexual abstinence, hormonal contraceptives (oral, injection, transdermal patch, or implant) or intrauterine device from 28 days before V3= Day 0 until 2 months after the 2nd vaccination.
16. Female participants: if lactating / nursing, or pregnant as per positive pregnancy test on V2.
17. Not suitable for inclusion in the opinion of the investigator.

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No